NCT01810042View on ClinicalTrials.gov

Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab

PHASE4CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Exudative Age-related Macular Degeneration
Interventions
DRUG

ranibizumab

0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.

Trial Locations (2)

602-739

Pusan National University Hospital, Busan

612-896

Haeundae Baik Hospital, Busan

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Pusan National University Hospital

OTHER